Hemogenyx Pharmaceuticals PLC Announces Institutional Investment
Hemogenyx Pharmaceuticals has secured a £600,000 institutional investment through the issuance of 60,000,000 new Ordinary Shares at 1p per share. The funds will support the imminent commencement of Phase I clinical trials for their HEMO-CAR-T therapy, targeting acute myeloid leukemia (AML) treatment. The new shares are expected to be admitted to trading on the London Stock Exchange Main Market around November 15, 2024. Following admission, the company's total issued share capital will comprise 1,401,815,988 ordinary shares.
Hemogenyx Pharmaceuticals ha ottenuto un investimento istituzionale di 600.000 sterline tramite l'emissione di 60.000.000 nuove azioni ordinarie a 1p per azione. I fondi supportano l'imminente avvio della fase I degli studi clinici per la loro terapia HEMO-CAR-T, mirata al trattamento della leucemia mieloide acuta (LMA). Le nuove azioni dovrebbero essere ammesse alla negoziazione sul mercato principale della Borsa di Londra intorno al 15 novembre 2024. Dopo l'ammissione, il capitale sociale totale emesso della società comprenderà 1.401.815.988 azioni ordinarie.
Hemogenyx Pharmaceuticals ha conseguido una inversión institucional de 600,000 libras a través de la emisión de 60,000,000 nuevas acciones ordinarias a 1p por acción. Los fondos apoyarán el inminente comienzo de los ensayos clínicos de fase I para su terapia HEMO-CAR-T, enfocada en el tratamiento de la leucemia mieloide aguda (LMA). Se espera que las nuevas acciones sean admitidas a cotización en el Mercado Principal de la Bolsa de Valores de Londres alrededor del 15 de noviembre de 2024. Tras la admisión, el capital social total emitido de la empresa consistirá en 1,401,815,988 acciones ordinarias.
Hemogenyx Pharmaceuticals는 주당 1펜스에 60,000,000개의 신규 보통주를 발행하여 600,000파운드의 기관 투자를 확보했습니다. 이 자금은 급성 골수성 백혈병(AML) 치료를 목표로 하는 HEMO-CAR-T 요법의 1상 임상 시험의 즉각적인 시작을 지원할 것입니다. 새로운 주식은 2024년 11월 15일 경 런던 증권거래소 주요 시장에 상장될 것으로 예상됩니다. 상장 후 회사의 총 발행 주식 자본은 1,401,815,988개의 보통주로 구성됩니다.
Hemogenyx Pharmaceuticals a sécurisé un investissement institutionnel de 600 000 £ par l'émission de 60 000 000 nouvelles actions ordinaires au prix de 1 pence par action. Les fonds soutiendront le lancement imminent des essais cliniques de phase I pour leur thérapie HEMO-CAR-T, visant à traiter la leucémie myéloïde aiguë (LMA). Les nouvelles actions devraient être admises à la négociation sur le marché principal de la Bourse de Londres autour du 15 novembre 2024. Après admission, le capital social total émis de la société comprendra 1 401 815 988 actions ordinaires.
Hemogenyx Pharmaceuticals hat eine institutionelle Investition in Höhe von 600.000 Pfund durch die Emission von 60.000.000 neuen Stammaktien zu je 1 Pence gesichert. Die Mittel werden den bevorstehenden Beginn der Phase-I-Klinikstudien für ihre HEMO-CAR-T-Therapie unterstützen, die auf die Behandlung der akuten myeloischen Leukämie (AML) abzielt. Es wird erwartet, dass die neuen Aktien um den 15. November 2024 an der Hauptbörse der Londoner Wertpapierbörse gehandelt werden. Nach der Zulassung wird das gesamte ausgegebene Aktienkapital des Unternehmens aus 1.401.815.988 Stammaktien bestehen.
- Secured £600,000 in institutional investment
- Advancing to Phase I clinical trials for HEMO-CAR-T therapy
- Strategic institutional investor backing demonstrates market confidence
- Share dilution through issuance of 60,000,000 new shares
Institutional Investment of £600,000
Hemogenyx Pharmaceuticals Secures £0.6m for Phase I Clinical Trials
LONDON, UNITED KINGDOM / ACCESSWIRE / November 11, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the biopharmaceutical group focused on developing new therapies for blood diseases, is pleased to announce that it was approached by an institutional investor and that this investor has subscribed £600,000, for the issue of 60,000,000 new Ordinary Shares at 1p per share.
The net proceeds of this subscription will be dedicated to the imminent commencement of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ("HEMO-CAR-T" or "HG-CT-1"), aimed at treating acute myeloid leukemia ("AML").
The Company will keep the Market informed of future developments as trials commence and develop.
An application is being made to the Main Market of the London Stock Exchange Main Market, and admission of the Subscription Shares to trading is expected on or around 15 November 2024 ("Admission"). The Subscription Shares will rank pari passu with the Company's existing Ordinary Shares.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are greatly encouraged by the confidence shown by our new institutional investor and are grateful for their support in advancing our mission to bring innovative treatments to patients with acute myeloid leukemia. This investment enables us to take a significant step forward with our HEMO-CAR-T program, moving into clinical trials and bringing us closer to providing a new therapeutic option for patients facing this aggressive disease."
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 1,401,815,988 ordinary shares. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
FAQ
How much institutional investment did Hemogenyx Pharmaceuticals (HOPHF) secure in November 2024?
What is the purpose of Hemogenyx Pharmaceuticals' (HOPHF) £600,000 fundraising in 2024?
How many new shares will Hemogenyx Pharmaceuticals (HOPHF) issue for the November 2024 investment?
